CDH1 and pancreatic neoplasm: Moreover, in line with recent work assessing Src kinase as an anti-invasive drug target (Avizienyte et al., 2002, Morton et al., 2010a, Nobis et al., 2013, Nobis et al., 2014), we demonstrate that the phase II drug dasatinib reverts E-cadherin mobilization in invasive pancreatic tumors and that this stabilization of junctions could partially explain its current anti-invasive role in this disease (T.J. Evans et al., 2012, ASCO, abstract).